United Therapeutics

Illumina

Amgen

Alnylam Pharmaceuticals

Biogen

Neurocrine Biosciences

Xencor

Exelixis

TG Therapeutics

Natera

Invesco Dynamic Biotechnology & Genome ETF

PBE tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.

Global X Artificial Intelligence & Technology ETF

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

ARK Web x.0 ETF

Global X Blockchain ETF

Global X Robotics & Artificial Intelligence ETF

Global X Genomics & Biotechnology ETF

iShares Cloud 5G and Tech ETF

iShares Genomics Immunology and Healthcare ETF

iShares Robotics & Artificial Intelligence Multisector ETF

First Trust Indxx Innovative Transaction & Process ETF

The 3D Printing ETF

ROBO Global Robotics and Automation ETF

Simplify Volt RoboCar Disruption and Tech ETF

Wisdomtree BioRevolution Fund

Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation's market share has grown, investment capacity - as measured by average days to trade - also has improved significantly.

Equity Market Cap For Technologically Enabled Innovation Likely To Grow Exponentially

Moderna

Defiance Nasdaq Junior Biotechnology ETF

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that offers protection against both the coronavirus and the seasonal flu. The new vaccine booster, which the biotech company calls mRNA-1073, combines Moderna's current coronavirus vaccine [.

Biotech ETFs Benefit From Moderna Dual Booster Shot News

ProShares Ultra Nasdaq Biotechnology

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This follows the Monday news that the FDA fully approved the Pfizer and BioNTech COVID-19 vaccine, making it the first vaccine in the U.S. [.

Could Biotech ETFs Get Another Boost From JNJ News?

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be awarded such a designation. The move could generate additional confidence for more businesses, schools, and universities to embrace the current vaccine mandates.

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

How Are Genomics ETFs Responding to Q2 Earnings?

VanEck Vectors Biotech ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

iShares Nasdaq Biotechnology ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

9 Best Biotech ETFs to Play High-Octane Trends

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

abrdn Life Sciences Investors 

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to help the mental deterioration seen in people living with Alzheimer's. The drug is also the first new medicine for the disease in nearly [.

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

Invesco Buyback Achievers ETF

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decline of dementia.

5 Top ETFs With Exposure To Biogen

Direxion Daily Healthcare Bull 3x Shares

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

abrdn Healthcare Investors 

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Global X Longevity Thematic ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Pacer BioThreat ETF

SPDR S&P Pharmaceuticals ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

Amplify Lithium & Battery Technology ETF

Global X Autonomous & Electric Vehicles ETF

Amplify Mobile Payments ETF

Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla and electric vehicles.

Play 3 Emerging ETF Trends to Follow Cathie Wood

The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management [.

Biopharma Here to Stay: The Long-Term Case for the PBE ETF

BioNTech SE

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion Pharmaceuticals (NASDAQ: ALXN). U.K.-based AstraZeneca, which is one of the prime players in the COVID-19 vaccine race, is valuing Alexion at $175 per share in this year's biggest pharmaceuticals takeover.

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.

2 Biotech Funds Poised for a Healthy Breakout

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Biotech ETFs to Shine on Coronavirus Antibodies Progress

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

Invesco DWA Healthcare Momentum ETF

After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.

3 Health Care ETFs Where Components Are Enduring Downgrades

Should You Invest in the Invesco Dynamic Biotechnology  Genome ETF (PBE)?

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.

Could Gilead News Be Good For Biotech ETFs?

News for Invesco Dynamic Biotechnology & Genome ETF ETF (PBE)